Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cancers|May 28, 2022
Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin LymphomaNaike Casagrande, Cinzia Borghese, Donatella Aldinucci
International Journal of Molecular Sciences|May 18, 2019
Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter ItDonatella Aldinucci, Cinzia Borghese, Naike Casagrande
Cancers|July 8, 2020
The CCL5/CCR5 Axis in Cancer ProgressionDonatella Aldinucci, Cinzia Borghese, Naike Casagrande
Cells|December 9, 2023
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869Naike Casagrande, Cinzia Borghese, Michele Avanzo, et al.
Pharmaceutics|May 1, 2020
Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel ResistanceCinzia Borghese, Naike Casagrande, Giuseppe Corona, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 21, 2024
In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedinNaike Casagrande, Cinzia Borghese, Giuseppe Corona, et al.
Cancer Letters|December 16, 2020
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphomaNaike Casagrande, Cinzia Borghese, Andrea Favero, et al.
British Journal of Haematology|December 1, 2010
IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretionDonatella Aldinucci, Marta Celegato, Cinzia Borghese, et al.
Haematologica|October 13, 2018
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growthNaike Casagrande, Cinzia Borghese, Lydia Visser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancerNaike Casagrande, Marta Celegato, Cinzia Borghese, et al.
Pageof 3